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Background: Chemical stimulation of the lateral hypothalamus (LH)
with carbachol induces antinociception which is antagonized by
blockade of orexin receptors in some pain modulatory sites in the tail-
flick test. In this study, we evaluated the role of orexin-1 and CB1
receptors in the periaqueductal gray matter (PAG), a critical pain
modulatory site, in mediation of antinociceptive responses induced by
LH stimulation in rats.
Methods: One hundred thirty-two adult male albino Wistar rats
weighing 180–250 g were unilaterally implanted with two separate
cannulae into the LH and ventrolateral PAG (vlPAG). Intra-vlPAG
administration of SB334867, as a selective orexin-1 receptor antagonist
(0.5, 1.5, 5, 15 and 50 nM), or AM251, as a selective CB1 receptor
antagonist (1, 3, 10, 30 and 100 nM), was performed just 5 min before
carbachol (125 nM) microinjection into the LH.
Results: Our findings showed that SB334867 or AM251 administration
dose dependently prevented the development of LH-induced
antinociception in rats. Treatment with two antagonists at the same time
could not intensify their effects in comparison with separate
administration of antagonists.
Conclusion: It seems that antinociceptive effect of intra-LH
administration of carbachol is mediated, at least partially, through the
activation of orexin-1 and CB1 receptors in the vlPAG.
Significance: This work demonstrates a pain modulatory role of the
orexinergic system via the PAG in hypothalamic-mediated analgesia
suggesting that orexins can be advantageously targeted to achieve
analgesia.
What does this study add?: OX1 receptor antagonist (SB334867)
administration into the ventrolateral periaqueductal gray matter (vlPAG)
dose dependently blocked the carbachol-induced antinociception. CB1
receptor antagonist (AM251) microinjection in the vlPAG prevented
carbachol-induced antinociception in a dose-dependent manner.
Concurrent administration of SB334867 and AM251 into the vlPAG did
not reinforce the antinociceptive responses.
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1. Introduction
Orexin-A and orexin-B (also called hypocretin-1 and
-2) are made exclusively in the perifornical area, lat-
eral and posterior hypothalamus and send their pro-
jections throughout the central nervous system
(CNS) (Lu et al., 2000; Marcus et al., 2001; Sadeghi
et al., 2013). Orexins activate two groups of G-pro-
tein-coupled receptors (GPCRs): the orexin-1 and -2
receptors (Ox1r and Ox2r). Ox1r is selective for
orexin-A, whereas Ox2r binds to both orexin-A and
-B (Sakurai et al., 1998). The broad projections of
orexinergic neurons carry implications for a variety
of functions including control of feeding behaviour,
sleep–wake cycle, cardiovascular function, hormone
secretion and, more recently, the modulation of
nociceptive processing (Ferguson and Samson, 2003;
Samson et al., 2005; Azhdari-Zarmehri et al., 2011).
Several lines of evidence have shown that inacti-
vation or electrical stimulation of the lateral
hypothalamus (LH) produces antinociception (Car-
stens et al., 1983; Tasker et al., 1987). Also, intra-LH
administration of carbachol, a cholinergic receptor
agonist, glutamate or morphine leads to certain
levels of antinociception in the acute (Behbehani
et al., 1988; Holden and Naleway, 2001) and persis-
tent inflammatory (Ezzatpanah et al., 2015) pain
models. There is a consensus that LH-induced
antinociception is directly or indirectly mediated
through the periaqueductal gray matter (PAG) and
rostroventromedial medulla (RVM), which ulti-
mately triggers the activation of descending nora-
drenergic pathways (Behbehani et al., 1988). Like
electrical stimulation, opioid administration into the
ventrolateral part of PAG (vlPAG), which is consid-
ered to be important in pain modulation, produces
antinociception (Lewis and Gebhart, 1977). Anatom-
ical evidences have indicated that orexinergic projec-
tions and orexin receptors are distributed along all
parts of pain circuitry, including the PAG (Peyron
et al., 1998; Horvath et al., 1999; Cheng et al.,
2003). Recently, it has been shown that orexin-A
microinjection into the PAG reduces formalin-
evoked nociceptive behaviours during the interphase
and late phase but not during the early phase and
intra-PAG administration of SB334867, a selective
Ox1r antagonist, antagonized the antinociceptive
effect of orexin-A (Azhdari-Zarmehri et al., 2011).
Also, previous studies have suggested that the
PAG is an important site for endocannabinoid-
mediated analgesia (Hohmann et al., 2005; Maione
et al., 2006). Endocannabinoids, such as anandamide
and 2-arachidonoylglycerol (2-AG), are lipid
neuromodulators in the brain and activate cannabi-
noid receptors (CB1 and CB2), both of which modu-
late nociception (Samineni et al., 2011). The finding
that intra-vlPAG microinjection of orexin-A can
increase hot-plate latency in rats confirms that
vlPAG is an important site of action for orexin-
induced antinociception (Azhdari-Zarmehri et al.,
2011; Ho et al., 2011). On the other hand, the
antinociceptive effect of orexin-A was markedly
reduced by cotreatment with AM251, a CB1 receptor
antagonist (Ho et al., 2011). This finding suggests
that there is an interaction between orexinergic and
endocannabinoid systems in the pain modulatory
role of PAG. Accordingly, in this study we aimed to
examine the involvement of PAG orexin-1 and CB1
receptors in mediation of antinociception induced by
intra-LH carbachol administration in the tail-flick
test as an animal model of acute pain.
2. Materials & Methods
2.1 Subjects
One hundred thirty-two adult male albino Wistar
rats (Pasteur Institute, Tehran, Iran) weighing 180–
250 g were used in these experiments. The rats were
kept in a vivarium maintained at a 12/12 h light/
dark cycle at room-controlled temperature (23  1
°C) with free access to food and water. Rats were
habituated to their new environment and handled
for a week before the beginning of experimental pro-
cedure. The animals were randomly allocated to dif-
ferent experimental groups. Each animal was used
only once. All experiments were executed in accor-
dance with the Guide for the Care and Use of Labo-
ratory Animals (National Institutes of Health
Publication No. 80-23, revised 1996) and were
approved by the Research and Ethics Committee of
Shahid Beheshti University of Medical Sciences.
2.2 Stereotaxic surgery
Rats were anesthetized with intraperitoneal injection
of ketamine 10% (100 mg/kg) and xylazine 2%
(10 mg/kg). Animals were placed in the stereotaxic
apparatus (Stoelting Company, Wood Dale, IL, USA).
The coordinates for the LH and vlPAG regions were
determined by the rat brain atlas (Paxinos and Wat-
son, 2007); vlPAG: AP = 7.75  0.15 mm caudal to
bregma; Lat = 0.5 mm; DV = 5.7 mm ventral from
the skull surface (23-gauge cannula, 9 mm length)
and LH: AP = 2.65  0.15 mm caudal to bregma,
Lat = 1.6 mm and DV = 8.8 mm ventral from the
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skull surface for the LH (23-gauge cannula, 12 mm
length). Two small holes were drilled in the skull
and stainless cannulae were unilaterally implanted
into the LH and vlPAG (left LH and vlPAG or right
LH and vlPAG), 1 mm above the appropriate injec-
tion place. The guide cannulae were secured in their
places using two stainless steel screws and dental
acryl cement. After the cement was completely dried
and hardened, two stainless steel stylets were used
to seal the guide cannulae during recovery period. A
single dose of penicillin-G 200,000 IU/mL (0.2–
0.3 mL/rat, intramuscular) was administered imme-
diately after surgery. Animals were individually
housed and allowed to recover for a period of 5–
7 days before the experiments.
2.3 Drugs and drug administration
Carbachol (Sigma-Aldrich, St. Louis, MO, USA) was
used as a cholinergic agonist and dissolved in the nor-
mal saline to prepare the 25 and 125 nM solutions.
SB334867 (Tocris Bioscience, Bristol, UK), as an Ox1r
antagonist, and AM251 [1-(2,4-dichlorophenyl)5-(4-
iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-
carboxamide], as a CB1 receptor antagonist (Sigma-
Aldrich, Steinheim, Germany), were dissolved in the
dimethyl sulfoxide (DMSO; Sigma-Aldrich) and appro-
priate solutions of SB334867 (1, 3, 10, 30 and 100 nM)
or AM251(0.5, 1.5, 5, 15 and 50 nM) were prepared.
All drugs were freshly prepared on the experiment day.
Microinjections were performed by lowering a stain-
less steel injector (a 30-gauge needle which was 1 mm
longer than the guide cannulae) into the vlPAG and/
or LH. The injector was attached to a 1-lL Hamilton
syringe by a polyethylene microtube (PE-20). Drug
microinjection (DMSO or antagonist) into the vlPAG
(in a total volume of 0.2 lL) was performed 5 min
before intra-LH administration of 0.5 lL of saline or
carbachol. The drug solutions or vehicles were infused
unilaterally over 60 s and was left for an extra 60 s to
facilitate the drug or vehicle diffusion. During the
infusion procedure, rats could freely move and all
efforts were made to reduce animal stress.
2.4 Tail-flick test
Tail-flick test is used as a model for studying the
acute pain. The nociceptive threshold was measured
by the tail-flick apparatus (Harvard Apparatus, Cam-
bridge, UK). The reaction time between the onset of
heat stimulus and the movement of tail was deter-
mined by an automatic sensor as tail-flick latency
(TFL). The light source was set at an intensity that
yields baseline TFL values in the range 3–4 s (about
45% of maximal light intensity). If the animal failed
to flick its tail within 10 s (cut-off point), the tail
was removed from the coil to prevent damage to the
skin (Ebrahimzadeh and Haghparast, 2011; Parvis-
han et al., 2011; Haghparast et al., 2012). In each
experiment, after measurement of baseline TFL val-
ues and administration of appropriate treatment, the
heat was applied in succession 3, 5 and 7 cm from
the caudal tip of tail. The average of three consecu-
tive post-drug TFLs, with time intervals of 30–40 s,
was used for measurement of percentage of maximal
possible effect (%MPE). %MPE was measured for
each 5, 15, 30, 45 and 60 time points. TFLs (sec) are
expressed either as raw post-drug TFL or %MPE. In
this study, we used %MPE which was calculated
from the following formula:
%MPE¼ Post-drugTFLðsecÞBaselineTFL ðsecÞ
Cut-off value ðsecÞBaseline TFL ðsecÞ 100
2.5 Experimental design
2.5.1 Dose–response effects of carbachol
microinjection into the LH in tail-flick test
In this set of experiments, carbachol solutions (25
and 125 nM) were microinjected into the LH before
the tail-flick test, whereas control animals received
saline into the LH instead of carbachol.
2.5.2 Effects of intra-vlPAG administration of OX1
receptor antagonist on the antinociception
induced by carbachol injection into the LH
To test the role of OX1 receptors located within the
vlPAG during the LH stimulation-induced antinoci-
ception in tail-flick test, baseline TFLs were mea-
sured. Then, 0.5, 1.5, 5, 15 and 50 nM solutions of
SB334867 were unilaterally injected into the vlPAG
5 min prior to intra-LH administration of carbachol
(125 nM). The procedure was followed by the tail-
flick test after 5 min. In the vehicle group, DMSO
was microinjected into the vlPAG and 2–4 min later
animals received saline into the LH. The DMSO
group received DMSO and carbachol into the vlPAG
and LH before the test, respectively.
2.5.3 Effects of intra-vlPAG administration of CB1
receptor antagonist on the antinociception
induced by carbachol injection into the LH
To examine the role of intra-vlPAG CB1 receptors in
the LH stimulation-induced antinociception, 1, 3, 10,
30 and 100 nM solutions of AM251 were
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unilaterally injected into the vlPAG 5 min prior to
the infusion of carbachol (125 nM), which was fol-
lowed by the tail-flick test after 5 min. In the vehicle
group, DMSO was microinjected into the vlPAG and
2–4 min later, animals received saline into the LH.
The DMSO group was microinjected with DMSO and
carbachol into the vlPAG and LH before the test,
respectively.
2.5.4 Interaction of intra-vlPAG administration of
OX1 receptor antagonist and CB1 receptor
antagonist on the antinociception induced by
administration of carbachol into the LH
In the last set of experiments, to examine the inter-
action of intra-vlPAG OX1 receptors and CB1 recep-
tors in the LH stimulation-induced antinociception,
0.5 nM SB334867 and 1 nM AM251 or 5 nM
SB334867 and 10 nM AM251 were injected into the
vlPAG, 5 min prior to the infusion of carbachol
(125 nM). The procedure was followed by tail-flick
test after 5 min. In the vehicle group, 2–4 min
before intra-LH administration of saline, DMSO was
microinjected into the vlPAG. The DMSO and carba-
chol were microinjected into the vlPAG and LH of
the DMSO group before the test.
The effect of carbachol injection into some brain
regions surrounding the LH or the effect of carbachol
administration into the LH in combination with
50 nM solution of SB334867 or 100 nM solution of
AM251 into some brain regions surrounding the
vlPAG was also examined to distinguish between the
results specific to drug injections into the LH and
vlPAG and those obtained from drug injections into
the neighbouring regions.
2.6 Histology
The animals were deeply anesthetized with ketamine
and xylazine after the experiments were accom-
plished. Transcardial perfusion was carried out with
0.9% saline and 10% formalin solution. The brains
were removed and cut coronally in 50 lm sections
through the cannulae placements. The neuroanatom-
ical locations of cannulae tips were confirmed using
Paxinos and Watson rat brain atlas (Paxinos and
Watson, 2007). Only the animals with correct cannu-
lae placements were included in the results (Fig. 1).
2.7 Statistics
The results attained are expressed as mean  SEM
(standard error of mean). The mean maximal
possible effect (%MPE) of drugs as an analgesic
index was subjected to two-way ANOVA followed by
Bonferroni’s test for multiple comparisons. To evalu-
ate the nociceptive responses, AUC was calculated as
raw pain scores 9 time by linear trapezoidal method
and a single value was used in statistical analyses.
The calculated AUC and pain score values in all
groups were subjected to one-way repeated mea-
sures ANOVA followed by protected Newman–Keuls
test for multiple comparisons. Unpaired student t-test
was used for comparison of AUC values of two
independent groups. The differences with p-values
less than 0.05 were considered to be statistically
significant.
3. Results
In each set of experiments, one-way ANOVA
showed that there are not any significant differences
among the baseline TFLs of animals. However, intra-
vlPAG administration of different solutions of
SB334867, a selective OX1 receptor antagonist, or
AM251, a CB1 receptor antagonist, changed the
TFLs. The effect of SB334867 or AM251 administra-
tion on LH-induced antinociception was compared to
the vehicle and DMSO groups as controls.
3.1 Dose–response effects of chemical
stimulation of the LH by carbachol on the
tail-flick test
In this experiment, we examined a dose–response
effect of carbachol solutions (25 and 125 nM)
microinjected into the LH on TFLs in the tail-flick test
in rats. Two-way ANOVA followed by Bonferroni’s
test [treatment effect: F (2,65) = 69.39, p < 0.0001;
time effect: F (4,65) = 0.5898, p = 0.6712; interaction
effect: F (8,65) = 0.4114, p = 0.9101; Fig. 2A]
affirmed that there are significant differences in %
MPEs as an index of antinociception between the con-
trol and experimental group (125 nM). In other
words, carbachol at the dose of 125 nM caused
antinociception which is seen as a significant increase
in %MPEs.
Furthermore, one-way ANOVA followed by Dun-
nett’s multiple comparison test [F (2,15) = 29.04,
p < 0.0001] showed significant increase in %MPEs
in carbachol group (125 nM) compared to the group
which had received 25 nM solution of carbachol and
control group (p < 0.001) (Fig. 2B). Therefore,
125 nM solution of carbachol was used in other set
of experiments.
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3.2 Effect of intra-vlPAG administration of OX1
receptor antagonist on the LH stimulation-
induced antinociception
Two-way ANOVA followed by Bonferroni’s test indi-
cated significant differences in antinociceptive
responses in DMSO group and groups which had
received carbachol following different solutions of
SB334867compared to the vehicle group [treatment
effect: F (6,175) = 59.04, p < 0.0001; time effect:
F (4,175) = 4667, p = 0.0013; interaction effect:
F (24,175) = 0.5271, p = 0.9666; Fig. 3A].
As it has been shown in Fig. 3B, one-way ANOVA
followed by Newman–Keuls multiple comparison test
indicated that there are significant differences in
AUC values calculated for %MPEs [F (6,41) = 29.62,
p < 0.0001] among the experimental and control
(vehicle and DMSO) groups. Data gained from these
experiments showed that intra-vlPAG administration
of SB334867 dose dependently prevents LH stimula-
tion-induced antinociception in rats. Intra-vlPAG
administration of 5, 15 and 50 nM solutions of
SB334867 (but not 0.5 and 1.5 nM) significantly
reduced AUC values in comparison with DMSO con-
trol group which had received carbachol into the LH
(p < 0.01 and p < 0.001, respectively; Fig. 3B).
3.3 Effect of intra-vlPAG administration of CB1
receptor antagonist on the LH stimulation-
induced antinociception
A dose–response effect of intra-vlPAG administration
of selective CB1 receptor antagonist, AM251, on the
antinociceptive response of intra-LH administration
of carbachol during a 60-min period was observed in
the following experiments. Two-way ANOVA
followed by Bonferroni’s test [Treatment effect:
F (6,175) = 49.57, p < 0.0001; Time effect: F (4,175)
Figure 1 Three coronal schematic microinjection sites (A) in the LH (○ = saline microinjection and ● = carbachol microinjection and ▲ = mis-
placement) and (B) in the PAG (○ = DMSO microinjection and ● = SB334867 and ■ = AM251 microinjection and ▲ = misplacement). All microin-
jections were performed unilaterally. LV, lateral ventricle; D3V, dorsal third ventricle; cc, corpus callosum; ic, internal capsule; CPu, caudate
putamen striatum; mt, mammillothalamic tract; DA, dorsal hypothalamic area; PeF, perifornicalnucleus; f, fornix; MCLH, magnocellular nucleus of
lateral hypothalamus; MTu, medial tuberal nucleus; VMH, ventromedial hypothalamic nucleus; PeFLH perifornical part of lateral hypothalamus; Pi,
pineal gland; DMPAG, dorsomedial periaqueductal area; LPAG, lateral periaqueductal gray; VLPAG, ventrolateral periaqueductal gray; Aq, aqueduct;
Me5, mesencephalic trigeminal nucleus; mlf, medial langitudinalfasciculus; dscp, decussation of the superior cerebellar; DLPAG, dorsolateral peri-
aqueductal gray; DRD, dorsal raphe nucleus (dorsal part); PrCnF, precuneiform area; 4n, trochlear nerve; DpMe, deep mesencephalic nucleus; DRL,
dorsal raphe nucleus (later part); DRV, dorsal raphe nucleus (ventral part); scp, superior cerebellar peduncle. Scale bar is 1 mm. In all rats cannulae
were placed in the left or right side.
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= 5.35, p = 0.0004; Interaction: F (24,175) = 0.2766,
p = 0.979] revealed that there are significant differ-
ences in %MPE values among the experimental and
control (vehicle and DMSO) groups (Fig. 4A).
In addition, one-way ANOVA followed by New-
man–Keuls multiple comparison test [F (6,41) =
29.31: p < 0.0001] indicated significant differences in
AUC values calculated for %MPEs among the exper-
imental and control groups. The results showed that
intra-vlPAG administration of AM251 prevents LH
stimulation-induced antinociception in rats in a
dose-dependent manner. In this respect, intra-vlPAG
administration of 10, 30 and 100 nM solutions of
AM251 (but not 1 and 3 nM) could significantly
(p < 0.05, p < 0.01 and p < 0.001, respectively)
reduce AUC values in comparison to DMSO control
group (Fig. 4B).
3.4 The effect of concurrent administration of
SB334867 and AM251 into the vlPAG on the
antinociception induced by carbachol
microinjection into the LH
To examine the interaction between the orexinergic
and cannabinoid systems in the vlPAG on the
antinociceptive response of carbachol, animals
Figure 2 Effect of unilateral administration of 25 and 125 nM solu-
tions of carbachol in the lateral hypothalamus (LH) on tail-flick laten-
cies in rats. (A) Maximal possible effect of two doses of carbachol 5,
15, 30, 45 and 60 min after microinjection and (B) area under the
curves (AUCs) calculated for %MPEs in 60-min period in tail-flick test as
a model of acute pain shown in A. Administration of 25 and 125 nM
solutions of carbachol reduced nociceptive responses compared to
the control group. Each point shows the mean  SEM for 5–6 rats.
**p < 0.01, ***p < 0.001 different from the saline control group.
Figure 3 Effect of unilateral microinjection of different solutions of SB334867, an OX1 receptor antagonist, in the ventrolateral periaqueductal
gray matter (vlPAG) on the antinociception induced by chemical stimulation of the lateral hypothalamus (LH). (A) maximal possible effect 5, 15, 30,
45 and 60 min after drug microinjection and (B) area under the curves (AUCs) calculated for %MPEs in 60-min period in tail-flick test as a model of
acute pain shown in A. Administration of 0.5, 1.5, 5, 15 and 50 nM solutions of SB3348675 min before intra-LH microinjection of carbachol
(125 nM) reduced LH-induced analgesia in a dose-dependent manner. Each point shows the mean  SEM for 5–7 rats. *p < 0.05, **p < 0.01,
***p < 0.001 different from the control (vehicle) group. ††p < 0.01, †††p < 0.01 different from the DMSO group.
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received two different doses of SB334867 and
AM251 into the vlPAG, 5 min prior to carbachol
infusion into the LH. Two-way repeated measures
ANOVA followed by Bonferroni’s test for %MPEs
indicated significant differences in antinociceptive
responses in DMSO group and groups which had con-
currently received carbachol and different doses of
SB334867 and AM251 compared to the control vehi-
cle group [Treatment effect: F (3,140) = 76.61,
p < 0.0001; Time effect: F (4,140) = 5.056, p = 0.008;
Interaction effect: F (12,140) = 0.802, p = 0.6479;
Fig. 5A]. Similarly, as shown in Fig. 5B, one-way
ANOVA followed by Newman–Keuls multiple com-
parison test showed significant differences in AUC
values calculated for %MPEs [F (3,31) = 38.22:
p < 0.0001] among the experimental and control
(vehicle and DMSO) groups. Data obtained from
these experiments revealed that intra-vlPAG admin-
istration of SB334867 and AM251 at the doses of 5
and 10 nM significantly reduced the %MPEs and
AUC values (p < 0.01) and reduced the LH stimula-
tion-induced antinociception in rats compared to the
DMSO group, but concurrent intra-vlPAG adminis-
tration of lower doses of SB334867 (0.5 nM) and
AM251 (1 nM) did not reduce the %MPEs and AUC
values in comparison to the DMSO group (Fig. 5B).
Furthermore, unpaired student t-test showed that
AUC value in group which in addition to carbachol
had received higher doses of antagonists was signifi-
cantly more than that which had received carbachol
and lower doses of SB334867 and AM251
(p < 0.01).
The results obtained from carbachol injection into
some areas close to the LH were significantly differ-
ent from those of DMSO group. In other words, it
did not have any antinociceptive effect. Also, admin-
istration of 50 nM solution of SB334867 or 100 nM
solution of AM251 into the some areas close to the
vlPAG before intra-LH administration of carbachol
could not antagonize LH-induced antinociception.
Accordingly, it can be assumed that observed results
are most likely due to effect of drug administration
into the LH and vlPAG not neighbouring areas.
4. Discussion
The purpose of this study was to evaluate the
involvement of orexin-1 and CB1 receptors in the
vlPAG in antinociceptive responses induced by LH
stimulation in rat. The major findings were as fol-
lows: (1) administration of 25 and 125 nM solutions
of carbachol into the LH produced antinociceptive
Figure 4 Effect of unilateral microinjection of different solutions of AM251, a CB1 receptor antagonist, in the ventrolateral periaqueductal gray
matter (vlPAG) on the antinociception induced by chemical stimulation of the lateral hypothalamus (LH). (A) maximal possible effect 5, 15, 30, 45
and 60 min after microinjection and (B) area under the curves (AUCs) calculated for %MPEs in 60-min period in tail-flick test as a model of acute
pain are shown in A. Administration of 1, 3, 10, 30 and 100 nM solutions of AM2515 min before intra-LH microinjection of carbachol (125 nM)
reduced LH-induced analgesia in a dose-dependent manner. Each point shows the mean  SEM for 5–8 rats. *p < 0.05, **p < 0.01, ***p < 0.001
different from the control (vehicle) group. †p < 0.05, ††p < 0.01, †††p < 0.01 different from the DMSO group.
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responses in the tail-flick test, (2) an OX1 receptor
antagonist (SB334867) administration into the
vlPAG dose dependently blocked the carbachol-
induced antinociception, (3) a CB1 receptor antago-
nist (AM251) microinjection in the vlPAG prevented
carbachol- induced antinociception in a dose-depen-
dent manner and (4) concurrent administration of
SB334867 and AM251 into the vlPAG did not rein-
force the antinociceptive responses.
Several studies have shown that the stimulation or
inactivation of LH produces antinociception (Behbe-
hani et al., 1988; Safari et al., 2009). The results of
first set of experiments in this study agreed with the
results of previous study showing that the chemical
stimulation of LH induces analgesia (Sadeghi et al.,
2013). In this study, two different solutions of carba-
chol were used: 25 and 125 nM. Carbachol solution
of 125 nM significantly caused antinociceptive
responses; hence, it was considered as the effective
dose in following experiments.
Neuroanatomical studies have suggested that there
is a physical association between LH and PAG. In
this respect, Behbehani et al. (1988) have indicated
that the majority of PAG neurons were excited and
tail-flick latency increased in response to the
electrical stimulation of LH. Furthermore, Peyron
et al. (1998) suggested that a relative high density of
orexinergic fibres project from the LH to the PAG
and finally terminate within the RVM and dorsal
horn of spinal cord (Peyron et al., 1998). There is an
increasing amount of evidence indicating that orex-
inergic system is involved in pain modulation. The
finding that intra-PAG microinjection of orexin-A
increased hot-plate latency in rat (Azhdari-Zarmehri
et al., 2011) confirms that PAG is an important site
of action for orexin-induced antinociception. In addi-
tion, previous studies have reported that the sys-
temic administration of orexin-A produced a dose-
related analgesia in hot-plate test in rats and the
intrathecal delivery of orexin-A-inhibited pain per-
ception (Bingham et al., 2001). In view of the fact
that the pain modulatory role of LH is mediated
directly or indirectly through the PAG (Millan,
2002), it can be suggested that the orexinergic path-
way from the LH to the PAG may be implicated in
control of pain (Azhdari-Zarmehri et al., 2011).
Given that carbachol increases the firing of orexin-
ergic system (Yamanaka et al., 2003), we attempted
to assess the role of intra-vlPAG orexin receptors on
the antinociception induced by carbachol stimulation
Figure 5 Effect of unilateral microinjection of two doses of SB334867, an OX1 receptor antagonist, and two doses of AM251, a CB1 receptor
antagonist, in the ventrolateral periaqueductal gray matter (vlPAG) on the antinociception induced by chemical stimulation of the lateral hypothala-
mus (LH). (A) maximal possible effect 5, 15, 30, 45 and 60 min after microinjection and (B) area under the curves (AUCs) calculated for %MPEs in
60-min period in tail-flick test as a model of acute pain shown in A. SB334867 (0.5 and 5 nM) and AM251 (1 and 10 nM) administration 5 min
before intra-LH microinjection of carbachol (125 nM) reduced LH-induced analgesia. Each point shows the mean  SEM for eight rats. *p < 0.05,
**p < 0.01, ***p < 0.001 different from the control (vehicle) group. †p < 0.05, ††p < 0.01 different from the DMSO group. ++p < 0.01 different
from two treatment groups.
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of LH. This study showed that carbachol causes
antinociceptive behaviours. The antinociceptive
effect of LH may be due to activation of orexin
receptors distributed in the different brain regions
involved in pain modulation, but reduction in anal-
gesia after intra-vlPAG administration of orexin-1
receptor antagonist indicated that LH analgesia was
at least partially mediated through the PAG orexin-1
receptors. It seems that orexins may directly excite
and depolarize the PAG neurons; an effect that
results in either the direct activation of RVM and
dorsal horn of the spinal cord or activation of
ascending pain modulatory pathways (Morgan et al.,
1989). Endocannabinoid mechanisms are strongly
implicated in endogenous antinociceptive mecha-
nisms (Hohmann et al., 2005; Suplita et al., 2005).
The release of endocannabinoids has been previously
observed following the induction of seizures by con-
vulsant drugs (Wallace et al., 2003). Earlier studies
have suggested that intra-PAG CB1 receptors modu-
late local inhibitory networks to regulate nociception
(Wallace et al., 2003). It seems that CB1 receptor-
induced analgesia is probably mediated through the
disinhibition of PAG GABAergic interneurons which
exert an intrinsic inhibitory tone on PAG neurons
(Pan et al., 1990; Meng et al., 1998; Vaughan et al.,
1999; Samineni et al., 2011). In this study, intra-
PAG administration of AM251, a CB1 antagonist,
dose dependently prevented the LH-induced
antinociception in rats. Given the fact that activation
of GPCRs like OX1r results in synthesis of endo-
cannabinoids (Ho et al., 2011), LH-induced analgesia
may be due to disinhibition of GABAergic interneu-
rons and indirect excitation of PAG neurons. In sup-
port of this finding, Ho et al. (2011) have shown
that the antinociceptive effect of orexin-A was mark-
edly reduced by cotreatment with AM251. This sup-
ports the idea that CB1 receptors are probably
implicated in orexin-induced analgesia whether they
are administrated directly into the PAG or released
into the PAG after LH stimulation. So, it can be con-
cluded that orexin-1 and CB1 receptors located in
the PAG play a major role in LH-induced antinoci-
ception in the tail-flick test. In other words, the pain
modulatory role of LH is partially mediated through
the interaction between the orexinergic and
cannabinoid systems in the PAG.
According to previous findings, SB334867 alone
had no effect on TFLs compared to control group
and there was no tonic orexin-1 receptor-mediated
inhibitory system in the ventral tegmental area and
nucleus accumbens in the tail-flick test (Sadeghi
et al., 2013). On the other hand, it is assumed that
cholinergic input from the basal forebrain neurons
to the orexinergic neurons might be implicated not
only in regulation of awake status but also in con-
trol of stressful situations (Tsujino and Sakurai,
2013). In this respect, previous study has demon-
strated that prepro-orexin (precursor of orexin-A
and -B) knockout mice showed less stress-induced
analgesia; demonstrating that orexin release in
stressful situation is involved in reduction in noci-
ception (Watanabe et al., 2005). Thus, although
there may not be a tonic orexin-1 receptor-mediated
inhibitory system in the PAG in the tail-flick test,
a hypothesis that needs more investigation, LH
releases orexin when encountered with emotional
and stressful situations.
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